Sign in with Google. Opens in new tab
bullish
Mankind Pharma: India Business to Recover, BSV Integration on Track. Maintain ADD
Mankind Pharma (Mankind) has witnessed a moderation in its India business in 9MFY25 to single digits (~9% YoY ex-BSV) from mid-double-digit growth in the past (13% CAGR over FY20-24)
What is covered in the Full Insight:
- Introduction to Mankind Pharma's Current Position
- Factors Affecting Recent Growth
- Future Growth Projections and BSV Integration
- Financial Implications and Market Expectations
- Key Risks and Investment Perspective
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 24-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- PointsBet (PBH AU): Betr's "Superior Offer"? In An Alternate Reality
- Xero (XRO AU): Index Flows Following the Capital Raise
- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
- NIFTY200 Momentum30 Index Rebalance: HUGE Turnover and Trade as Financials Shine
- S&P/ASX Indices: Proposed Methodology Changes & The BIG September Rebalance
Top Unpaywalled Insights
More »- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x